CBS 2019
CBSMD教育中心
中 文

Congestive Heart Failure

Abstract

Recommended Article

Transcatheter Interatrial Shunt Device for the Treatment of Heart Failure With Preserved Ejection Fraction (REDUCE LAP-HF I [Reduce Elevated Left Atrial Pressure in Patients With Heart Failure]): A Phase 2, Randomized, Sham-Controlled Trial Association of Prior Left Ventricular Ejection Fraction With Clinical Outcomes in Patients With Heart Failure With Midrange Ejection Fraction Clinical Phenogroups in Heart Failure With Preserved Ejection Fraction: Detailed Phenotypes, Prognosis, and Response to Spironolactone Respiratory Syncytial Virus and Associations With Cardiovascular Disease in Adults Impact of epicardial adipose tissue on cardiovascular haemodynamics, metabolic profile, and prognosis in heart failure SPECT and PET in ischemic heart failure Heart failure with preserved ejection fraction: from mechanisms to therapies A trial to evaluate the effect of the sodium-glucose co-transporter 2 inhibitor dapagliflozin on morbidity and mortality in patients with heart failure and reduced left ventricular ejection fraction (DAPA-HF)

Recommandation Statement2019 Feb 21:CIR0000000000000641.

JOURNAL:Circulation. Article Link

Cardio-Oncology: Vascular and Metabolic Perspectives: A Scientific Statement From the American Heart Association

Campia U, American Heart Association Council on Peripheral Vascular Disease; Council on Arteriosclerosis, Thrombosis and Vascular Biology; and Council on Cardiovascular and Stroke Nursing. Keywords: AHA Scientific Statements; cardiovascular diseases; medical oncology; therapeutics

FULL TEXT PDF